Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 201 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
201 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) receive an allogeneic, off‑the‑shelf iPSC‑derived CAR T product (FT836) targeting stress‑inducible MICA/MICB (engineered to reduce antigen shedding) as monotherapy or combined with trastuzumab (HER2), cetuximab (EGFR), and/or paclitaxel. Multi‑arm cohorts assess safety and preliminary activity to establish RP2D for the combination regimens.
ClinicalTrials.gov ID: NCT07216105
TrialFetch AI summary: Adults with advanced/metastatic solid tumors who have exhausted standard options receive IV TJ101, a bispecific EGFR/B7-H3 antibody–drug conjugate, every 3 weeks in dose escalation with biomarker-driven expansion cohorts. Excludes prior topoisomerase I inhibitor or TOP1i-ADC exposure, active ILD/pneumonitis, significant ocular or uncontrolled cardiovascular disease, and active CNS disease unless treated and stable.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults (ECOG 0–1) with refractory/recurrent locally advanced or metastatic solid tumors—particularly tissue factor–expressing cancers such as HNSCC, NSCLC, esophagogastric, colorectal, pancreatic ductal adenocarcinoma, cervical, endometrial, or urothelial carcinoma—after appropriate prior systemic therapy (prior-line limits vary by study part) are eligible. Treatment is STRO-004, a tissue factor–targeting antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given as monotherapy with dose escalation/expansion or combined with pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT07227168
TrialFetch AI summary: Enrolls adults with relapsed/refractory locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation (ECOG 0–1, measurable disease) after progression on, intolerance of, or ineligibility for standard approved therapies. Patients receive oral once-daily PLX-61639, a SMARCA2 targeted protein degrader (synthetic-lethal strategy in SMARCA4-deficient tumors; DCAF16-linked, proteasome-mediated SMARCA2 degradation).
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with metastatic/advanced NSCLC, gastroesophageal, colorectal, hepatocellular, pancreatic, or head and neck squamous cell carcinoma that has progressed on or is intolerant to standard systemic therapy (ECOG 0–2; measurable disease) receive DM005 (YH013) monotherapy IV Q3W. DM005 is a first-in-human bispecific antibody–drug conjugate targeting EGFR and c-MET, intended to preferentially bind EGFR/MET co-expressing tumors to enhance internalization and cytotoxic payload delivery, with dose escalation/expansion to define safety/MTD and assess preliminary activity.
ClinicalTrials.gov ID: NCT06515990
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313